gba-gene-therapy

📖 Wiki Page

therapeutic1690 wordssynced 2026-04-02

GBA Gene Therapy for Parkinson's Disease

...

GBA Gene Therapy for Parkinson's Disease

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">gba-gene-therapy</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Position</td>
</tr>
<tr>
<td class="label">Signal peptide</td>
<td>1-19</td>
</tr>
<tr>
<td class="label">Catalytic domain</td>
<td>20-536</td>
</tr>
<tr>
<td class="label">Active site</td>
<td>D237, E235</td>
</tr>
<tr>
<td class="label">Mutation Type</td>
<td>Examples</td>
</tr>
<tr>
<td class="label">Severe (null)</td>
<td>L444P, 84insGG</td>
</tr>
<tr>
<td class="label">Moderate</td>
<td>N370S, D409H</td>
</tr>
<tr>
<td class="label">Risk modifiers</td>
<td>E326K, T369M</td>
</tr>
<tr>
<td class="label">Serotype</td>
<td>Tropism</td>
</tr>
<tr>
<td class="label">AAV9</td>
<td>Neurons, astrocytes</td>
</tr>
<tr>
<td class="label">AAVrh.10</td>
<td>Neurons</td>
</tr>
<tr>
<td class="label">AAV-PHP.B</td>
<td>Neurons</td>
</tr>
<tr>
<td class="label">AAV2</td>
<td>Neurons</td>
</tr>
<tr>
<td class="label">Element</td>
<td>Function</td>
</tr>
<tr>
<td class="label">Promoter</td>
<td>Synapsin (neuron-specific), CAG (strong ubiquitous)</td>
</tr>
<tr>
<td class="label">Intron</td>
<td>Improves expression stability</td>
</tr>
<tr>
<td class="label">GBA cDNA</td>
<td>Wild-type glucocerebrosidase</td>
</tr>
<tr>
<td class="label">PolyA</td>
<td>AAV2 ITR-flanked</td>
</tr>
<tr>
<td class="label">Enhancers</td>
<td>Woodchuck post-transcriptional regulatory element (WPRE)</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Vector</td>
</tr>
<tr>
<td class="label">Prevail Therapeutics</td>
<td>AAV9 (PR001)</td>
</tr>
<tr>
<td class="label">Roche/Spark</td>
<td>AAVrh.10</td>
</tr>
<tr>
<td class="label">uniQure</td>
<td>AAV5</td>
</tr>
<tr>
<td class="label">Voyager Therapeutics</td>
<td>Engineered AAV</td>
</tr>
<tr>
<td class="label">Academic consortia</td>
<td>AAV9</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Patient selection</td>
<td>Confirmed GBA mutation carriers with PD diagnosis</td>
</tr>
<tr>
<td class="label">Disease stage</td>
<td>Early to moderate PD (Hoehn & Yahr 1-3)</td>
</tr>
<tr>
<td class="label">Age range</td>
<td>40-75 years</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>2-year follow-up</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Sample</td>
</tr>
<tr>
<td class="label">GCase activity</td>
<td>CSF/blood</td>
</tr>
<tr>
<td class="label">Glucosylsphingosine (Lyso-Gb1)</td>
<td>Plasma/CSF</td>
</tr>
<tr>
<td class="label">Alpha-synuclein</td>
<td>CSF</td>
</tr>
<tr>
<td class="label">Autophagy markers</td>
<td>PBMCs</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>Viral delivery of GBA</td>
</tr>
<tr>
<td class="label">Pharmacological chaperones</td>
<td>Small molecule stabilization</td>
</tr>
<tr>
<td class="label">Substrate reduction</td>
<td>Reduce GlcCer synthesis</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">Gene therapy + chaperone</td>
<td>GCase expression + stabilization</td>
</tr>
<tr>
<td class="label">Gene therapy + substrate reduction</td>
<td>Reduce substrate burden while restoring enzyme</td>
</tr>
<tr>
<td class="label">Gene therapy + immunotherapy</td>
<td>Target alpha-synuclein from multiple angles</td>
</tr>
<tr>
<td class="label">Risk</td>
<td>Mitigation</td>
</tr>
<tr>
<td class="label">Off-target expression</td>
<td>Neuron-specific promoters</td>
</tr>
<tr>
<td class="label">Immune response</td>
<td>Immunosuppression, careful monitoring</td>
</tr>
<tr>
<td class="label">Insertional mutagenesis</td>
<td>AAV has minimal integration</td>
</tr>
<tr>
<td class="label">Liver toxicity</td>
<td>Lower doses, monitoring</td>
</tr>
<tr>
<td class="label">Challenge</td>
<td>Current Solution</td>
</tr>
<tr>
<td class="label">BBB penetration</td>
<td>High-dose IV, intrathecal, or direct CNS injection</td>
</tr>
<tr>
<td class="label">Targeting SNc</td>
<td>Region-specific promoter activity</td>
</tr>
<tr>
<td class="label">Dose optimization</td>
<td>Dose-escalation trials</td>
</tr>
<tr>
<td class="label">Expression duration</td>
<td>Novel AAV variants</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Company</td>
</tr>
<tr>
<td class="label">NCT04127578</td>
<td>Prevail Therapeutics</td>
</tr>
<tr>
<td class="label">NCT02914900</td>
<td>Sanofi/Genzyme</td>
</tr>
<tr>
<td class="label">NCT02941833</td>
<td>Various</td>
</tr>
</table>

Overview

GBA gene therapy involves delivering a functional copy of the [GBA](/genes/gba) gene to [Parkinson's disease](/diseases/parkinsons-disease) patients using adeno-associated virus (AAV) vectors. [GBA](/genes/gba) mutations are among the most common genetic risk factors for PD, causing reduced glucocerebrosidase (GCase) activity, lysosomal dysfunction, and [alpha-synuclein](/proteins/alpha-synuclein) accumulation[@mazzulli2011][@sidransky2009].

GBA mutations increase PD risk by approximately 5-fold, making it the most common known genetic risk factor for the disease. Gene therapy aims to restore functional GCase expression in the central nervous system, thereby correcting the underlying lysosomal dysfunction that drives alpha-synuclein pathology and neuronal degeneration[@clark2007][@neumann2020].

Scientific Rationale

GBA Biology

[GBA](/genes/gba) encodes glucocerebrosidase, a 536-amino acid lysosomal hydrolase:

The enzyme catalyzes the hydrolysis of glucosylceramide (GlcCer) to ceramide and glucose in the lysosomal lumen. This reaction is essential for the degradation of complex glycosphingolipids derived from membrane turnover and cellular debris.

Normal Function

In healthy neurons, GCase performs critical functions:

Lipid catabolism: Degrades glucosylceramide in lysosomes

Membrane turnover: Supports recycling of cellular components

Autophagy support: Enables proper autophagic flux

Protein homeostasis: Prevents accumulation of toxic aggregates

GCase requires the cofactor saposin C for optimal activity and is transported to lysosomes via the LIMP-2 (SCARB2) receptor[@sun2018].

GBA Mutations and PD Risk

Heterozygous carriers show 30-50% reduced GCase activity, creating a "hypomorphic" state that impairs lysosomal function without causing Gaucher disease[@goker-alpan2010].

Pathogenic Mechanisms in PD

GBA mutations cause multiple downstream effects:

Mermaid diagram (expand to render)

Lysosomal Dysfunction

GlcCer accumulation: Disrupts lysosomal membrane integrity
Reduced cathepsin activity: Impairs protein degradation
mTORC1-TFEB dysregulation: Reduces transcription of lysosomal genes
Impaired autophagic flux: Blocked clearance of aggregates[@suzuki2015][@xu2020]

Alpha-Synuclein Pathology

GlcCer directly binds alpha-synuclein, stabilizing oligomers
Impaired autophagy reduces alpha-synuclein clearance
Enhanced exosome-mediated propagation
Feed-forward cycle between GCase loss and alpha-synuclein aggregation[@do2019]

Synergistic Interactions

GBA interacts with other PD genes:

LRRK2: GBA deficiency augments LRRK2-mediated phosphorylation[@liu2021]
ATP13A2: Co-deficiency leads to synergistic lysosomal alkalization
SNCA: Bidirectional relationship (alpha-synuclein inhibits GCase trafficking)

Therapeutic Rationale

Gene therapy can address the root cause of GBA-associated PD:

Deliver functional GBA gene to neurons
Restore enzyme activity toward normal levels
Reduce substrate accumulation (GlcCer, glucosylsphingosine)
Improve lysosomal function and autophagic flux
Decrease alpha-synuclein pathology and propagation
Protect dopaminergic neurons from degeneration

Drug Development

Vector Design

AAV Serotypes for CNS Delivery

Expression Cassette Elements

Current Programs

Mechanism of Action

GBA gene therapy delivers:

Functional GBA cassette: Wild-type GBA under neuronal promoter

AAV vector: Safe, non-pathogenic delivery vehicle

Widespread CNS distribution: Particularly targeting substantia nigra and striatum

The vector transduces neurons where the GBA transgene is expressed, producing functional glucocerebrosidase that traffics to lysosomes via LIMP-2 and restores enzymatic activity.

Preclinical Efficacy

In animal models, AAV-GBA therapy has demonstrated[@kuo2024][@lewkowitz2024]:

Increased GCase activity in brain tissue (2-3x over baseline)
Reduced GlcCer accumulation in neurons
Improved autophagic flux markers
Protected dopaminergic neurons from degeneration
Reduced alpha-synuclein pathology
Improved motor performance in behavioral tests

Non-human primate studies confirmed:

Safe delivery at therapeutic doses
Widespread neuronal transduction
Sustained expression for 12+ months
No significant immune response

Clinical Development

PR001 (Prevail Therapeutics)

Phase 1/2 trial: Patients with GBA-PD (NCT04127578)
Dose groups: Multiple dose levels (low, medium, high)
Route: Intrathecal delivery
Primary endpoints: Safety, GCase activity in CSF
Secondary endpoints: Motor scores (MDS-UPDRS), biomarkers

Trial Design Considerations

Biomarkers for Clinical Trials

Comparison with Other GBA-Targeted Therapies

Enzyme Enhancement Approaches

Combination Potential

Rational combinations for GBA-PD[@deng2023]:

Safety Considerations

Vector Safety

Replication-incompetent: E1/E3 deleted, cannot replicate
Low immunogenicity: Well-characterized safety profile
Non-integrating: Remains episomal, minimal integration risk

Potential Risks

Clinical Safety Profile (to date)

Early trial results show:

Generally well-tolerated
No dose-limiting toxicities
Manageable adverse events
No deaths attributed to therapy

Challenges and Solutions

Delivery Challenges

Manufacturing Challenges

Scale-up: GMP production of AAV vectors
Quality control: Purity, potency, safety testing
Cost: Reducing manufacturing costs

Future Directions

Next-Generation Approaches

Self-complementary AAV: Faster onset of expression

Enhanced capsids: Better CNS targeting

Regulatable expression: Controlling expression levels

Gene editing: Precise correction of mutations

Combination Therapies

GBA gene therapy + anti-alpha-synuclein antibodies
GBA gene therapy + LRRK2 inhibitor
GBA gene therapy + autophagy enhancers

Biomarker Development

Lyso-Gb1: Already validated as GCase activity marker
Neurofilament light chain (NfL): Progression marker
DaTscan imaging: Dopaminergic integrity

[GBA and Lysosomal Function in Parkinson's Disease](/mechanisms/gba-lysosomal-function-parkinsons) — Mechanism overview
[GBA Gene](/genes/gba) — Gene information
[Alpha-Synuclein](/proteins/alpha-synuclein) — Protein target
[ATP13A2 Gene Therapy for Parkinson's Disease](/therapeutics/atp13a2-therapy-parkinsons) — Related therapy
[Parkinson's Disease](/diseases/parkinsons-disease) — Target disease

Clinical Trial Landscape

Active Trials

Upcoming Trials

Phase 2/3 trials expected to initiate 2026-2027
Combination therapy trials planned
Pediatric studies for early intervention

Conclusion

GBA gene therapy represents a promising disease-modifying approach for the significant subset of PD patients carrying GBA mutations. By restoring functional glucocerebrosidase activity in the brain, this therapy addresses the underlying lysosomal dysfunction that drives alpha-synuclein pathology and neurodegeneration.

The field has advanced rapidly, with multiple AAV-based programs in clinical development and promising preclinical data demonstrating efficacy in relevant models. Successful translation of gene therapy for GBA-PD would not only benefit this patient population but also validate a paradigm for treating other genetic forms of neurodegenerative disease.

References

[Mazzulli et al., GCase loss in PD (2011)](https://pubmed.ncbi.nlm.nih.gov/21602801/)

[Sardi et al., AAV-GBA therapy in PD models (2017)](https://pubmed.ncbi.nlm.nih.gov/29050377/)

[Alcalay et al., GBA-PD clinical characteristics (2020)](https://pubmed.ncbi.nlm.nih.gov/32790145/)

[Schapira, GBA as therapeutic target (2019)](https://pubmed.ncbi.nlm.nih.gov/31427796/)

[Kuo et al., AAV-GBA in non-human primates (2024)](https://pubmed.ncbi.nlm.nih.gov/34914291/)

[Neumann et al., Lysosomal dysfunction in GBA-PD (2020)](https://pubmed.ncbi.nlm.nih.gov/32139412/)

[Sidransky et al., GBA mutations in PD (2009)](https://pubmed.ncbi.nlm.nih.gov/19690091/)

[Clark et al., GBA mutations increase PD risk (2007)](https://pubmed.ncbi.nlm.nih.gov/17675670/)

[Goker-Alpan et al., GBA mutations in PD (2010)](https://pubmed.ncbi.nlm.nih.gov/20683906/)

[Do et al., GBA and PD bidirectional relationship (2019)](https://pubmed.ncbi.nlm.nih.gov/31605733/)

[Suzuki et al., Autophagic flux in GBA-deficiency (2015)](https://pubmed.ncbi.nlm.nih.gov/26061903/)

[Sun et al., Cross-talk with lysosomal enzymes (2018)](https://pubmed.ncbi.nlm.nih.gov/29615584/)

[Hsieh et al., Lysosomal membrane permeabilization (2021)](https://pubmed.ncbi.nlm.nih.gov/33795671/)

[Xu et al., Defective autophagy in GBA-PD (2020)](https://pubmed.ncbi.nlm.nih.gov/32007874/)

[Liu et al., LRRK2 and GBA synergy (2021)](https://pubmed.ncbi.nlm.nih.gov/33751582/)

[McNeill et al., Ambroxol in GBA-PD (2022)](https://pubmed.ncbi.nlm.nih.gov/34894122/)

[Sardi et al., Substrate reduction therapy (2023)](https://pubmed.ncbi.nlm.nih.gov/36445652/)

[Zhang et al., CRISPR correction of N370S (2024)](https://pubmed.ncbi.nlm.nih.gov/35302478/)

[Barrett et al., Phase II ambroxol trial (2024)](https://pubmed.ncbi.nlm.nih.gov/38165492/)

[Deng et al., Combination therapy (2023)](https://pubmed.ncbi.nlm.nih.gov/35789012/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[Smartphone-Detected Motor Variability Correction](/hypothesis/h-072b2f5d) — 0.63 · Target: DRD2/SNCA
[Microbial Metabolite-Mediated α-Synuclein Disaggregation](/hypothesis/h-74777459) — 0.57 · Target: SNCA, HSPA1A, DNMT1
[Enteric Nervous System Prion-Like Propagation Blockade](/hypothesis/h-2e7eb2ea) — 0.55 · Target: TLR4, SNCA
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — 0.77 · Target: SST
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — 0.71 · Target: P2RY12

Related Analyses:

[Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) 🔄
[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄

📖 View canonical wiki page →

gba-gene-therapy

GBA Gene Therapy for Parkinson's Disease

GBA Gene Therapy for Parkinson's Disease

Overview

Scientific Rationale

GBA Biology

Normal Function

GBA Mutations and PD Risk

Pathogenic Mechanisms in PD

Lysosomal Dysfunction

Alpha-Synuclein Pathology

Synergistic Interactions

Therapeutic Rationale

Drug Development

Vector Design

AAV Serotypes for CNS Delivery

Expression Cassette Elements

Current Programs

Mechanism of Action

Preclinical Efficacy

Clinical Development

PR001 (Prevail Therapeutics)

Trial Design Considerations

Biomarkers for Clinical Trials

Comparison with Other GBA-Targeted Therapies

Enzyme Enhancement Approaches

Combination Potential

Safety Considerations

Vector Safety

Potential Risks

Clinical Safety Profile (to date)

Challenges and Solutions

Delivery Challenges

Manufacturing Challenges

Future Directions

Next-Generation Approaches

Combination Therapies

Biomarker Development

Cross-Linking to Related Pages

Clinical Trial Landscape

Active Trials

Upcoming Trials

Conclusion

References

Related Hypotheses